The Use and Role of Mesalamine in the Treatment of Ulcerative Colitis: A Literature Review

One of the most common forms of Inflammatory bowel disease amongst adolescents, with chronic relapsing and inflammation involving the colonic mucosa, is ulcerative colitis (UC). Though various possible causative theories have been linked to the development of this condition, the standard treatment approach for mild to moderate cases of UC has been mesalamine. Its use in UC has been primarily due to its anti-inflammatory properties, such as the inhibition of inflammatory cytokines, and a less common side effect profile. The main objective of this study has been to highlight underutilized clinical strategies and support evidence-informed decisions regarding the use of mesalamine for both achieving and sustaining remission in patients with UC across varying age groups. Hence, through this paper, the key results and findings, such as the modest risk of repercussions associated with mesalamine, its suitability for prolonged use, and its chemoprotective feature, will provide more confidence among both physicians and patients in using mesalamine for UC.